Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Analysts expect the New York-based company to report quarterly earnings at 57 cents per share, down from 63 cents per share ...

Earnings To Watch: Pfizer (PFE) Reports Q4 Results Tomorrow

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market open. Here’s what ...

Pfizer Reshapes Portfolio With New Partnerships Oncology Push And Pricing Shifts

Pfizer (NYSE:PFE) licensed Novavax’s Matrix-M adjuvant technology to support future vaccine development. The company received FDA Breakthrough Therapy Designation for a combination of Sutent and ...

Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance

Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...

Pfizer (PFE) Valuation Check As Investors Reassess Recent Shareholder Returns

Is Back on Investors’ Radar Pfizer (PFE) is attracting fresh attention after a period of mixed share performance, with the ...
U.S. News & World Report

Analysis-Pfizer Could Hold a Trump Card in Its Bid for Metsera

(Reuters) -U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech firm ...

Pfizer inks $530M deal for Novavax Matrix-M adjuvant technology to boost vaccine pipeline

Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to ...